Vanda Pharmaceuticals (VNDA) Competitors

Vanda Pharmaceuticals (NASDAQ:VNDA) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking and valuation.

Does the media favor VNDA or NVAX?

In the previous week, Novavax had 24 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 29 mentions for Novavax and 5 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.44 beat Novavax's score of 0.44 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	8 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Neutral

Do institutionals & insiders hold more shares of VNDA or NVAX?

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 8.9% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of Novavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has better valuation & earnings, VNDA or NVAX?

Vanda Pharmaceuticals has higher earnings, but lower revenue than Novavax. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$198.77M	1.33	-$18.90M	-$0.32	-13.98
Novavax	$682.16M	1.51	-$545.06M	-$1.33	-4.82

Is VNDA or NVAX more profitable?

Vanda Pharmaceuticals has a net margin of -9.51% compared to Novavax's net margin of -32.18%. Novavax's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-9.51%	-3.49%	-2.90%
Novavax	-32.18%	N/A	-17.05%

Which has more volatility and risk, VNDA or NVAX?

Vanda Pharmaceuticals has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500. Comparatively, Novavax has a beta of 3.15, suggesting that its stock price is 215% more volatile than the S&P 500.

Do analysts recommend VNDA or NVAX?

Vanda Pharmaceuticals presently has a consensus price target of $16.50, suggesting a potential upside of 268.72%. Novavax has a consensus price target of $18.00, suggesting a potential upside of 180.94%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Novavax	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Does the MarketBeat Community believe in VNDA or NVAX?

Novavax received 308 more outperform votes than Vanda Pharmaceuticals when rated by MarketBeat users. Likewise, 74.06% of users gave Novavax an outperform vote while only 66.30% of users gave Vanda Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Vanda Pharmaceuticals	Outperform Votes 543 66.30%	Underperform Votes 276 33.70%
Novavax	Outperform Votes 851 74.06%	Underperform Votes 298 25.94%

Summary

Vanda Pharmaceuticals and Novavax tied by winning 9 of the 18 factors compared between the two stocks.